Last reviewed · How we verify
Videx (DIDANOSINE)
Videx (generic name: DIDANOSINE) is a Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor Small molecule drug developed by Bristol-Myers Squibb. It is currently FDA-approved (first approved 1991) for Human immunodeficiency virus infection.
Videx (didanosine) is a small molecule nucleoside analog reverse transcriptase inhibitor developed by Bristol Myers Squibb, currently owned by the same company. It was FDA-approved in 1991 for the treatment of human immunodeficiency virus (HIV) infection. Videx is off-patent and has multiple generic manufacturers. Key safety considerations include its short half-life of 1.4 hours and variable bioavailability of 38%. As an off-patent medication, Videx is widely available in generic forms.
At a glance
| Generic name | DIDANOSINE |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
- Human immunodeficiency virus infection
Common side effects
- Pancreatitis
- Pancreatitis
- Pancreatitis
- Pancreatitis
Serious adverse events
- Pancreatitis (fatal)
- Pancreatitis (fatal)
- Pancreatitis (pediatric, higher doses)
- Pancreatitis (pediatric, lower doses)
- Lactic acidosis/symptomatic hyperlactatemia
- Liver failure
- Hepatic steatosis
- Portal hypertension (non-cirrhotic)
- Hepatitis
- Anaphylactoid reaction
Drug interactions
- enoxacin
- ganciclovir
- indinavir
- itraconazole
- ketoconazole
- lomefloxacin
- methadone
- norfloxacin
- ofloxacin
- pentamidine
- ribavirin
- tenofovir
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2,PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Prospective Cohort of Children With HIV Infection
- Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam (PHASE1)
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (PHASE3)
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
- Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Videx CI brief — competitive landscape report
- Videx updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Videx
What is Videx?
What is Videx used for?
Who makes Videx?
What is the generic name of Videx?
What drug class is Videx in?
When was Videx approved?
What development phase is Videx in?
What are the side effects of Videx?
Related
- Drug class: All Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor drugs
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Human immunodeficiency virus infection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing